This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Papamichael, D. Articles by Rohatiner, A. Z.S. Search for Related Content PubMed PubMed Citation Articles by Papamichael, D. Articles by Rohatiner, A. Z.S. Social Bookmarking                            What's this?

Immunocytoma: A Retrospective Analysis From St Bartholomew's Hospital—1972 to 1996

From the Imperial Cancer Research Fund (ICRF) Department of Medical Oncology, Departments of Histopathology and Haematology, St Bartholomew's Hospital, West Smithfield, London, and ICRF Medical Statistics Group, Institute of Health Sciences, Headington, Oxford, United Kingdom.

Address reprint requests to A.Z.S. Rohatiner, MD, ICRF Department of Medical Oncology, 45 Little Britain, St Bartholomew's Hospital, London EC1A 7BE, United Kingdom; emaila.rohatiner{at}icrf.icnet.uk

PURPOSE: To analyze the presentation features and outcome for patients with immunocytoma (IMC) managed at St Bartholomew's Hospital (SBH), London, United Kingdom, between 1972 and 1996. Outcome was compared with that of patients with small lymphocytic lymphoma (SLL)/B-cell chronic lymphocytic leukemia (B-CLL) treated at SBH during the same period.

PATIENTS AND METHODS: One hundred twenty-six patients with newly diagnosed IMC were identified. Patients were subclassified (using the Kiel classification) as having lymphoplasmacytoid (n =92), lymphoplasmacytic (n = 24), polymorphous (n = 9), or undetermined (n = 1) IMC. Six patients (5%) had stage I to IIE disease; the rest had advanced disease. Treatment was given according to disease stage. Seven patients were managed expectantly.

RESULTS: Eighty-two (69%) of 119 patients responded to treatment, but complete remission was seen in only 15 (13%) of 119. Treatment failed in 29 (24%) of 119 patients. There were three treatment-related deaths; five patients were not assessable for response. When survival of patients with IMC was compared with that of patients with B-CLL/SLL, a significant difference was found (P < .01); this difference was maintained when only patients in whom the diagnosis was based on lymph node biopsy were considered (P = .01). A comparison of the three IMC subgroups showed that there was a trend (P = .06) toward a difference between B-CLL/SLL and the lymphoplasmacytoid subtype.

CONCLUSION: Patients diagnosed with IMC are generally older and present with advanced disease. Conventional therapies usually result in incomplete responses of short duration. Overall, these results support the proposed World Health Organization reclassification of IMC to include lymphoplasmacytoid lymphoma (Kiel classification) as a variant of B-CLL/SLL.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. Kriangkum, B. J. Taylor, S. P. Treon, M. J. Mant, T. Reiman, A. R. Belch, and L. M. Pilarski Molecular Characterization of Waldenstrom's Macroglobulinemia Reveals Frequent Occurrence of Two B-Cell Clones Having Distinct IgH VDJ Sequences Clin. Cancer Res., April 1, 2007; 13(7): 2005 - 2013. [Abstract] [Full Text] [PDF]

				S E Coupland, M Hellmich, C Auw-Haedrich, W R Lee, I Anagnostopoulos, and H Stein Plasmacellular differentiation in extranodal marginal zone B cell lymphomas of the ocular adnexa: an analysis of the neoplastic plasma cell phenotype and its prognostic significance in 136 cases Br J Ophthalmol, March 1, 2005; 89(3): 352 - 359. [Abstract] [Full Text] [PDF]

				J. Kriangkum, B. J. Taylor, S. P. Treon, M. J. Mant, A. R. Belch, and L. M. Pilarski Clonotypic IgM V/D/J sequence analysis in Waldenstrom macroglobulinemia suggests an unusual B-cell origin and an expansion of polyclonal B cells in peripheral blood Blood, October 1, 2004; 104(7): 2134 - 2142. [Abstract] [Full Text] [PDF]

				L. Baldini, M. Brugiatelli, S. Luminari, M. Lombardo, F. Merli, S. Sacchi, P. Gobbi, M. Liberati, L. Cavanna, M. Colombi, et al. Treatment of Indolent B-Cell Nonfollicular Lymphomas: Final Results of the LL01 Randomized Trial of the Gruppo Italiano per lo Studio dei Linfomi J. Clin. Oncol., April 15, 2003; 21(8): 1459 - 1465. [Abstract] [Full Text] [PDF]

				J. M. Foran, A. Z. S. Rohatiner, D. Cunningham, R. A. Popescu, P. Solal-Celigny, M. Ghielmini, B. Coiffier, P. W. M. Johnson, C. Gisselbrecht, F. Reyes, et al. European Phase II Study of Rituximab (Chimeric Anti-CD20 Monoclonal Antibody) for Patients With Newly Diagnosed Mantle-Cell Lymphoma and Previously Treated Mantle-Cell Lymphoma, Immunocytoma, and Small B-Cell Lymphocytic Lymphoma J. Clin. Oncol., January 14, 2000; 18(2): 317 - 317. [Abstract] [Full Text] [PDF]